Certolizumab Pegol
Indication
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
NICE TA574 - Certolizumab pegol for treating moderate to severe plaque psoriasis
Red
Brand:
Cimzia®
Nice TA:
574
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Skin
Background
1.1 Certolizumab pegol is recommended as an option for treating plaque psoriasis in adults, only if:
- the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and
- the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and
- the lowest maintenance dosage of certolizumab pegol is used (200 mg every 2 weeks) after the loading dosage and
- the company provides the drug according to the commercial arrangement.